Clin2
NCT07133633Possibly a fitRecruiting

Tulisokibart for X-ray confirmed axial spondyloarthritis

Radiographic Axial Spondyloarthritis

Treatments studied

Part of Bones, joints & muscles clinical trials.

This study tests a new medicine called Tulisokibart for people with a type of inflammatory arthritis that affects the spine and pelvic joints, specifically when X-rays show changes. The goal is to see if it can reduce symptoms like pain and stiffness.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
315 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You must have a diagnosis of axial spondyloarthritis (a type of inflammatory arthritis that mainly affects the spine and pelvic joints) with back pain that started before age 45 and has lasted at least 3 months.
  • You must have changes on X-rays of your spine or pelvis that are typical of ankylosing spondylitis, confirmed by a central reader.
  • Your disease must be active (causing symptoms) both at the screening visit and when you start the study.
  • You must have tried at least one NSAID (like ibuprofen or naproxen) and it didn't help enough or caused side effects. You may not have used any biologic medications, or you may have tried up to two different kinds but they didn't work or caused side effects.
  • You cannot have other types of inflammatory arthritis (like rheumatoid arthritis or psoriatic arthritis). You also cannot have had cancer (other than fully treated skin cancer) in the last 5 years, and you cannot have an active infection.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07486960Recruiting· Phase 2
Study of Tulisokibart for Psoriatic Arthritis

This trial tests a new drug called tulisokibart for people with psoriatic arthritis (PsA), a condition that causes joint pain and skin plaques. It may help if you have not tried certain biologic medications or if they did not work well.

Sun City, Arizona
NCT06430801Recruiting· Phase 3
Study of tulisokibart for moderate to severe Crohn's disease

This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.

Dothan, Alabama
NCT06651281Recruiting· Phase 3
Long-term safety and effectiveness of tulisokibart for Crohn's or colitis

This study gives tulisokibart to people who already took part in an earlier trial for Crohn's disease or ulcerative colitis and are still benefiting from it. The goal is to see how safe and effective the medicine is over a longer period.

Bristol, Connecticut
NCT06197009Not yet recruiting· Phase 2
Study of SCT650C for Active Axial Spondyloarthritis

This trial tests an investigational medication called SCT650C for people with active axial spondyloarthritis. It aims to see if it can reduce pain and inflammation better than current treatments.

Ankara, Hacettepe Mh.
NCT07295509Recruiting· Phase 2/Phase 3
Testing picankibart for active psoriatic arthritis

This trial tests a new drug called picankibart to see if it helps people with active psoriatic arthritis who haven't gotten enough relief from standard treatments like NSAIDs or non-biologic DMARDs. It may be an option if you have at least 3 tender and 3 swollen joints and active or past plaque psoriasis.

Hangzhou, Zhejiang
NCT06112665Recruiting· Phase 4
Tofacitinib for early active axial spondyloarthritis

This trial tests whether tofacitinib (a pill that reduces inflammation) can help people with early-stage axial spondyloarthritis, a type of arthritis that mainly affects the spine and pelvis. It's for those who have had symptoms for 2 years or less and have active disease with signs of inflammation in MRI or blood tests.

Berlin

Hear when a new Radiographic Axial Spondyloarthritis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.